New combo therapy aims to control advanced endometrial cancer
NCT ID NCT05819892
First seen Jan 17, 2026 · Last updated Jun 15, 2026 · Updated 27 times
Summary
This early-phase trial tests whether combining chemotherapy, radiation, and the immunotherapy drug dostarlimab is safe and tolerable for people with stage IIIC node-positive endometrial cancer. About 21 participants will receive chemoradiation followed by chemotherapy plus dostarlimab as maintenance therapy. The goal is to control the cancer, not to cure it, and researchers will closely monitor side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ENDOMETRIAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.